| Treatment | No. of trials(references) | No. of patients treated† (biological/placebo groups) | Duration of follow-up (weeks) | No. of patients with at least 1 serious infection in biotherapy groups and by dose group(no. of participants) | No. of patients with at least 1 serious infection in placebo groups(no. of participants) |
| Rituximab | 3 10 22 23 | 1143 (745/398) | 24–48 | 0 Rituximab 500 mg (124) | 6 (398) |
| 17 Rituximab 1000 mg (621) | |||||
| Abatacept | 5 9 24–28 | 2945 (1960/985) | 24–48 | 0 Abatacept 0.5 mg/kg (26) | 18 (985) |
| 2 Abatacept 2 mg/kg (137) | |||||
| 47 Abatacept 10 mg/kg (1797) | |||||
| Anakinra | 4 8 29–31 | 2771 (2062/729) | 24 | 0 Anakinra 0.04 mg/kg (63) | 4 (729) |
| 0 Anakinra 0.1 mg/kg (74) | |||||
| 0 Anakinra 0.4 mg/kg (77) | |||||
| 0 Anakinra 1 mg/kg (59) | |||||
| 0 Anakinra 2 mg/kg (72) | |||||
| 0 Anakinra 30 mg per day (119) | |||||
| 1 Anakinra 75 mg per day (116) | |||||
| 25 Anakinra 100 mg per day (1367) | |||||
| 4 Anakinra 150 mg per day (116) |
*Serious infection was defined as life-threatening, requiring intravenous antibiotics or hospitalisation.
†Number of patients who received at least one dose of study medication in this arm of randomisation and were analysed.